The Dark Side of RNA

Strange as it seems, a new class of diseases is emerging that appears to be caused by mutations in untranslated regions of RNA. The protein-coding sequence of the relevant gene is uninterrupted and yet features of the disease flourish. Exactly how this happens is the subject of keen investigation that now promises to further intensify, following the publication in August of an important discovery. Researchers at the University of Minnesota showed that myotonic dystrophy, known formally as dyst

Written bySteve Bunk
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Researchers at the University of Minnesota showed that myotonic dystrophy, known formally as dystrophia myotonica (DM), derives primarily from a mutation in untranslated RNA.1 Their finding, which concerns DM type 2, corroborates evidence of a decade earlier that DM1 is similarly caused.2 The two mutations, which occur on chromosomes 19 and 3, respectively, both result in the multisystemic signs and symptoms that characterize myotonic dystrophy. Moreover, both mutations are repeat expansions-nucleotide sequences that recur adjacently many more times than normal. A third type of DM is thought to exist, but it has not been identified.

"I think this will be considered the major pathogenic mechanism for DM," asserts Laura P.W. Ranum, the DM2 paper's senior author and a University of Minnesota associate professor of genetics, cell biology, and development. The paper points out that untranslated repeat expansions also are involved in two types of spinocerebellar ataxia, SCA8 and SCA10. However, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies